Adiposity and Endothelin Receptor Function

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03583866

Acronym

END-RF

Enrollment

Registered

2018-07-12

Start date

2018-05-21

Completion date

2026-01-31

Last updated

2025-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

blood pressure, microdialysis

Brief summary

Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.

Detailed description

The proposed study is designed to investigate the influence of adiposity on ETB receptor function and subsequent vascular responses. The combination of ET-1, ET-3, and the respective ETA and ETB receptor antagonists will be used to provide insight into the mechanisms of ETB receptor dysfunction in the presence of adiposity. Previous studies have revealed elevations in circulating ET-1 in obese individuals; therefore, we predict that obese subjects will exhibit 1) ETB receptor dysfuncton compared to lean subjects and 2) an improvement in ETB receptor dysfunction following treatment with Candesartan.

Interventions

DRUGCandesartan

7 days of Candesartan (16mg/day)

DRUGPlacebo

7 days of Placebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

• If you are an adult between the ages of 18-40 year old

Exclusion criteria

* Evidence of cardiovascular, pulmonary, renal, hepatic, cerebral, or metabolic disease * Evidence of pregnancy * Using medications that affect vascular tone (i.e., nitrates, etc.) * Use of any anticoagulants (i.e. aspirin) * Anemia * If you are postmenopausal * If you have uncontrolled hypertension (treated resting SBP \>140 mm Hg or DBP \>90 mm Hg)

Design outcomes

Primary

Measure	Time frame	Description
Percentage Change in Flow-Mediated Dilation (FMD)	pre-treatment Baseline and 7 days post-treatment	Change in Brachial artery FMD induced by reactive hyperemia assessed vascular endothelial function at baseline and several hours after treatment.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026